FLG client Axcient, Inc., announced today that they raised a $15.5 million Series C round from Scale Venture Partners; Rory O’Driscoll will join the board of directors. Company press release. FLG partner: John Finegan.
Recent News
Cuervo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention
Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
Read More
Testimonials
“When I become CEO of TapInfluence in 2015, I knew there would be challenges trying to evolve the culture and changing the business model from a managed services business to a software as a service (SaaS) business. Most fail because of the amount of discipline required to stay the course despite potential disruptions in revenue, team dynamics, and customer relationships. As we evaluated the prospects of a new funding round, I needed a CFO who could be a leader and trusted business partner that was credible with my board of directors and potential investors, strategic to develop our business models, scenario planning and forecasts, and operationally focused to evolve to a SaaS business model. I was extremely pleased that my FLG Partner, Ken Chow and I closed our funding round with our board’s support at a strong valuation and on time. This made a huge difference for our business and could not have done without FLG’s support.”
Promise Phelon, CEO, TapInfluenceRead More